Weight Loss Jab Blocks ‘Master Controller’ for Obesity Prevention
- Researchers are developing a new weight-loss medication, RES-010, designed to address the underlying biological factors contributing to obesity.
- These processes include fat metabolism, mitochondrial function (energy production within cells), and the institution and function of body fat.
- In studies presented at the annual meeting of the European Association for the Study of Diabetes in Vienna, Austria, obese mice treated with a weekly injection of RES-010...
New Weight-loss Jab Shows promise by Targeting Obesity’s Root Causes
Table of Contents
Published September 25, 2025
Understanding RES-010
Researchers are developing a new weight-loss medication, RES-010, designed to address the underlying biological factors contributing to obesity. The drug functions by blocking miR-22, an RNA molecule identified as a “master controller” of several processes related to weight gain.
These processes include fat metabolism, mitochondrial function (energy production within cells), and the institution and function of body fat. The goal is to promote lasting weight loss by positively influencing these key areas.
Promising Results in Animal Studies
In studies presented at the annual meeting of the European Association for the Study of Diabetes in Vienna, Austria, obese mice treated with a weekly injection of RES-010 experienced weight loss despite maintaining the same diet as a control group. Notably, the mice did not regain the lost weight after the drug was discontinued.
How RES-010 Works
RES-010 targets miR-22, which plays a critical role in regulating how the body processes fats and generates energy. By blocking this molecule, the drug aims to restore healthy metabolic function and promote lasting weight management.